Denali Therapeutics price target lowered to $32 from $35 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
manilatimes22m
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana” or the "Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
KSTP-TV13m
An Israeli TV reporter lost his ability to speak clearly. AI is helping him get back on air
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
Jewish Insider35m
Daily Kickoff
Secondly, I think, in a prior time, the government of Israel — by the way, like most governments — would have focused ...